A panel of experts to the U.S. FDA on Thursday recommended allowing Amarin Corp Plc’s fish-oil derived drug to be used as add-on therapy for reducing the chance of heart attacks and strokes in high-risk patients with cardiovascular disease. The panel voted 16-0 in favor of expanding approval, potentially opening up a multi-billion dollar opportunity for the company which has only one drug, Vascepa, in the market. Vascepa, a highly purified omega-3 fatty acid derived from fish oil, won U.S. approval in 2012 to lower high levels of triglycerides — a type of blood fat that can increase …read more
Source:: Yahoo Finance
